Insider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) COO Sells 2,274 Shares of Stock

Blueprint Medicines Co. (NASDAQ:BPMC) COO Christina Rossi sold 2,274 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $95.10, for a total transaction of $216,257.40. Following the sale, the chief operating officer now owns 71,657 shares in the company, valued at approximately $6,814,580.70. The trade was a 3.08 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Blueprint Medicines Trading Up 1.3 %

Shares of NASDAQ:BPMC traded up $1.24 on Monday, hitting $97.62. 542,247 shares of the company’s stock were exchanged, compared to its average volume of 690,484. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27. The business’s 50 day simple moving average is $90.97 and its two-hundred day simple moving average is $98.04. The stock has a market capitalization of $6.20 billion, a price-to-earnings ratio of -45.68 and a beta of 0.59. Blueprint Medicines Co. has a 12 month low of $70.39 and a 12 month high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.08. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The business had revenue of $128.20 million during the quarter, compared to the consensus estimate of $127.56 million. During the same period in the previous year, the company posted ($2.20) earnings per share. The firm’s revenue was up 126.5% on a year-over-year basis. Analysts anticipate that Blueprint Medicines Co. will post -3.68 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on BPMC shares. JPMorgan Chase & Co. began coverage on shares of Blueprint Medicines in a research note on Thursday, November 14th. They set an “overweight” rating and a $126.00 target price on the stock. StockNews.com raised shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Friday, November 8th. Wells Fargo & Company cut their price objective on shares of Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating for the company in a report on Thursday, October 31st. Needham & Company LLC reaffirmed a “buy” rating and set a $135.00 price objective on shares of Blueprint Medicines in a report on Friday, November 15th. Finally, UBS Group began coverage on shares of Blueprint Medicines in a report on Thursday, October 24th. They set a “neutral” rating and a $88.00 price objective for the company. One research analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Blueprint Medicines currently has a consensus rating of “Moderate Buy” and a consensus target price of $122.11.

Institutional Investors Weigh In On Blueprint Medicines

A number of large investors have recently bought and sold shares of BPMC. Hsbc Holdings PLC acquired a new position in Blueprint Medicines in the second quarter valued at approximately $1,060,000. Comerica Bank raised its stake in shares of Blueprint Medicines by 2,582.9% during the 1st quarter. Comerica Bank now owns 10,839 shares of the biotechnology company’s stock worth $1,028,000 after buying an additional 10,435 shares during the period. Federated Hermes Inc. raised its stake in shares of Blueprint Medicines by 27.8% during the 2nd quarter. Federated Hermes Inc. now owns 62,354 shares of the biotechnology company’s stock worth $6,721,000 after buying an additional 13,579 shares during the period. SG Americas Securities LLC raised its stake in shares of Blueprint Medicines by 82.8% during the 2nd quarter. SG Americas Securities LLC now owns 21,684 shares of the biotechnology company’s stock worth $2,337,000 after buying an additional 9,819 shares during the period. Finally, Nicholas Investment Partners LP acquired a new position in shares of Blueprint Medicines during the 2nd quarter worth approximately $4,377,000.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.